Literature DB >> 29540496

Exacerbations of COPD.

Christian Viniol1, Claus F Vogelmeier2.   

Abstract

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. While COPD is a mainly chronic disease, a substantial number of patients suffer from exacerbations. Severe exacerbations are related to a significantly worse survival outcome. This review summarises the current knowledge on the different aspects of COPD exacerbations. The impact of risk factors and triggers such as smoking, severe airflow limitation, bronchiectasis, bacterial and viral infections and comorbidities is discussed. More severe exacerbations should be treated with β-agonists and anticholinergics as well as systemic corticosteroids. Antibiotic therapy should only be given to patients with presumed bacterial infection. Noninvasive ventilation is indicated in patients with respiratory failure. Smoking cessation is key to prevent further COPD exacerbations. Other aspects include choice of pharmacotherapy, including bronchodilators, inhaled corticosteroids, phosphodiesterase-4 inhibitors, long-term antibiotics and mucolytics. Better education and self-management as well as increased physical activity are important. Influenza and pneumococcal vaccination is recommended. Treatment of hypoxaemia and hypercapnia reduce the rate of COPD exacerbations, while most interventional bronchoscopic therapies increase exacerbation risk within the first months after the procedure.
Copyright ©ERS 2018.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29540496     DOI: 10.1183/16000617.0103-2017

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  71 in total

Review 1.  Digital health for COPD care: the current state of play.

Authors:  Hang Ding; Farhad Fatehi; Andrew Maiorana; Nazli Bashi; Wenbiao Hu; Iain Edwards
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

2.  Gallic acid ameliorates COPD-associated exacerbation in mice.

Authors:  Esha Singla; Gayatri Puri; Vivek Dharwal; Amarjit S Naura
Journal:  Mol Cell Biochem       Date:  2020-09-23       Impact factor: 3.396

Review 3.  Animal Models Reflecting Chronic Obstructive Pulmonary Disease and Related Respiratory Disorders: Translating Pre-Clinical Data into Clinical Relevance.

Authors:  Lloyd Tanner; Andrew Bruce Single
Journal:  J Innate Immun       Date:  2019-09-17       Impact factor: 7.349

4.  PARC/CCL18 is Associated with Inflammation, Emphysema Severity and Application of Inhaled Corticosteroids in Hospitalized COPD Patients.

Authors:  Hongxia Duan; Long Liang; Xinyang Liu; Shuanshuan Xie; Changhui Wang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-05-10

5.  Serum levels of visfatin, sirtuin-1, and interleukin-6 in stable and acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Hassan Ghobadi; Sara Mokhtari; Mohammad Reza Aslani
Journal:  J Res Med Sci       Date:  2021-02-27       Impact factor: 1.852

6.  Chronic obstructive pulmonary disease: Is serum magnesium level a risk factor for its acute exacerbation?

Authors:  Ketan Kshirsagar; Virendra C Patil
Journal:  Caspian J Intern Med       Date:  2021-03

7.  30-day Readmission After an Acute Exacerbation of Chronic Obstructive Pulmonary Disease is Associated with Cardiovascular Comorbidity.

Authors:  Aylin Ozgen Alpaydin; Saliha Selin Ozuygur; Ceyda Sahan; Kemal Can Tertemiz; Richard Russell
Journal:  Turk Thorac J       Date:  2021-09

8.  Estimated Cardiorespiratory Hospitalizations Attributable to Influenza and Respiratory Syncytial Virus Among Long-term Care Facility Residents.

Authors:  Elliott Bosco; Robertus van Aalst; Kevin W McConeghy; Joe Silva; Patience Moyo; Melissa N Eliot; Ayman Chit; Stefan Gravenstein; Andrew R Zullo
Journal:  JAMA Netw Open       Date:  2021-06-01

Review 9.  Infection-Associated Mechanisms of Neuro-Inflammation and Neuro-Immune Crosstalk in Chronic Respiratory Diseases.

Authors:  Belinda Camp; Sabine Stegemann-Koniszewski; Jens Schreiber
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

10.  Precision cut lung slices: an ex vivo model for assessing the impact of immunomodulatory therapeutics on lung immune responses.

Authors:  Guanghui Liu; Linnea Särén; Helena Douglasson; Xiao-Hong Zhou; Per M Åberg; Anna Ollerstam; Catherine J Betts; Kinga Balogh Sivars
Journal:  Arch Toxicol       Date:  2021-06-30       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.